Vesicoureteral Reflux Associated Renal Damage: Congenital Reflux Nephropathy and Acquired Renal Scarring

2010 ◽  
Vol 184 (1) ◽  
pp. 265-273 ◽  
Author(s):  
Caig Peters ◽  
H. Gil Rushton
2020 ◽  
Vol 14 (8) ◽  
pp. 683-696
Author(s):  
Flávia C Valério ◽  
Renata D Lemos ◽  
Ana L de C Reis ◽  
Letícia P Pimenta ◽  
Érica LM Vieira ◽  
...  

Aim: This article aimed to review the role of cytokines, chemokines, growth factors and cellular adhesion molecules as biomarkers for vesicoureteral reflux (VUR) and reflux nephropathy (RN). Methods: We reviewed articles from 1979 onward by searching PubMed and Scopus utilizing the combination of words: ‘VUR’ or ‘RN’ and each one of the biomarkers. Results: Genetic, inflammatory, fibrogenic, environmental and epigenetic factors responsible for renal scarring need to be better understood. TGF-β, IL-10, IL-6, IL-8 and TNF seem to exert a role in VUR particularly in RN based on the current literature. Serum levels of procalcitonin have been also associated with high-grade VUR and RN. These molecules should be more intensively evaluated as potential biomarkers for renal scarring in VUR. Conclusion: Further studies are necessary to define which molecules will really be of utility in clinical decisions and as therapeutic targets for VUR and RN.


2015 ◽  
Vol 8 (1) ◽  
pp. 96-103 ◽  
Author(s):  
Adam Rensing ◽  
Paul Austin

Vesicoureteral reflux [VUR] remains a common problem seen by pediatric providers. Despite a great deal of research, the debate regarding how to screen and treat patients reremains tense and controversial. This review seeks to summarize the management of VUR with emphasis on recent published findings in the literature and how they contribute to this debate. The goals of managing VUR include preventing future febrile urinary tract infections [FUTI], renal scarring, reflux nephropathy and hypertension. The topdown approach with upper tract imaging and selective vesicocystourethrogram [VCUG] is an emerging alternative approach in the evaluation of children after their first FUTI. The elimination of bladder and bowel dysfunction [BBD] is an important management strategy to prevent further FUTIs, regardless of treatment choice. Antibiotic prophylaxis is a safe and effective modality to sterilize the urinary tract. Endoscopic treatment of VUR is an attractive modality in select patients, although some concerns remain regarding its effectiveness and durability as compared to to the gold standard of open or laparoscopic ureteroneocystostomy. Lastly, further research is required to determine the most effective algorithm to evaluate the pediatric patient after the first febrile UTI.


2021 ◽  
Vol 9 ◽  
Author(s):  
Göran Läckgren ◽  
Christopher S. Cooper ◽  
Tryggve Neveus ◽  
Andrew J. Kirsch

Vesicoureteral reflux (VUR) is associated with increased risks of urinary tract infection, renal scarring and reflux nephropathy. We review advancements over the last two decades in our understanding and management of VUR. Over time, the condition may resolve spontaneously but it can persist for many years and bladder/bowel dysfunction is often involved. Some factors that increase the likelihood of persistence (e.g., high grade) also increase the risk of renal scarring. Voiding cystourethrography (VCUG) is generally considered the definitive method for diagnosing VUR, and helpful in determining the need for treatment. However, this procedure causes distress and radiation exposure. Therefore, strategies to reduce clinicians' reliance upon VCUG (e.g., after a VUR treatment procedure) have been developed. There are several options for managing patients with VUR. Observation is suitable only for patients at low risk of renal injury. Antibiotic prophylaxis can reduce the incidence of UTIs, but drawbacks such as antibiotic resistance and incomplete adherence mean that this option is not viable for long-term use. Long-term studies of endoscopic injection have helped us understand factors influencing use and the effectiveness of this procedure. Ureteral reimplantation is still performed commonly, and robot-assisted laparoscopic methods are gaining popularity. Over the last 20 years, there has been a shift toward more conservative management of VUR with an individualized, risk-based approach. For continued treatment improvement, better identification of children at risk of renal scarring, robust evidence regarding the available interventions, and an improved VUR grading system are needed.


Urology ◽  
2013 ◽  
Vol 81 (1) ◽  
pp. 173-177 ◽  
Author(s):  
Kibriya Fidan ◽  
Yasar Kandur ◽  
Bahar Buyukkaragoz ◽  
Umit Ozgur Akdemir ◽  
Oguz Soylemezoglu

PEDIATRICS ◽  
1981 ◽  
Vol 67 (3) ◽  
pp. 392-400 ◽  

The role of VUR in the development and progression of renal damage in children is universally acknowledged. The risk/benefit ratio of therapeutic intervention, whether medical or surgical, continues to be debated. This carefully controlled prospective, longitudinal, multispecialty, international trial aims to establish a rational basis for the treatment of VUR.


2008 ◽  
Vol 2008 ◽  
pp. 1-5 ◽  
Author(s):  
Michiel Costers ◽  
Rita Van Damme-Lombaerts ◽  
Elena Levtchenko ◽  
Guy Bogaert

The main goal of the management of vesicoureteral reflux (VUR) is prevention of recurrent urinary tract infections (UTIs), and thereby prevention of renal parenchymal damage possibly ensuing from these infections. Long-term antibiotic prophylaxis is common practice in the management of children with VUR, as recommended in 1997 in the guidelines of the American Urological Association. We performed a systematic review to ascertain whether antibiotics can be safely discontinued in children with VUR and whether prophylaxis is effective in the prevention of recurrent UTIs and renal damage in these patients. Several uncontrolled studies indicate that antibiotic prophylaxis can be discontinued in a subset of patients, that is, school-aged children with low-grade VUR, normal voiding patterns, kidneys without hydronephrosis or scars, and normal anatomy of the urogenital system. Furthermore, a few recent randomized controlled trials suggest that antibiotic prophylaxis offers no advantage over intermittent antibiotic therapy of UTIs in terms of prevention of recurrent UTIs or new renal damage.


Urology ◽  
1973 ◽  
Vol 2 (5) ◽  
pp. 534-538 ◽  
Author(s):  
Stephen W. Zimmerman ◽  
David T. Uehling ◽  
Peter M. Burkholder

Sign in / Sign up

Export Citation Format

Share Document